Cargando…
T099: High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621500/ http://dx.doi.org/10.1097/01.HS9.0000890964.54059.2c |
| _version_ | 1784821570500296704 |
|---|---|
| author | Moskowitz, Alison J. Shah, Gunjan Schöder, Heiko Ganesan, Nivetha Hancock, Helen Davey, Theresa Perez, Leslie Sohail, Samia Santarosa, Alayna Capadona, Charisse Munayirji, Brittney Kumar, Anita Lahoud, Oscar Batlevi, Connie Hamlin, Paul Straus, David J. Owens, Colette Caron, Philip Intlekofer, Andrew Hamilton, Audrey Horwitz, Steven Falchi, Lorenzo Johnson, William Palomba, Lia Noy, Ariela Matasar, Matthew Pongas, Georgios Salles, Gilles Vardhana, Santosha Sanin, Beatriz Wills Yahalom, Joachim Dogan, Ahmet Zelenetz, Andrew Moskowitz, Craig H. |
| author_facet | Moskowitz, Alison J. Shah, Gunjan Schöder, Heiko Ganesan, Nivetha Hancock, Helen Davey, Theresa Perez, Leslie Sohail, Samia Santarosa, Alayna Capadona, Charisse Munayirji, Brittney Kumar, Anita Lahoud, Oscar Batlevi, Connie Hamlin, Paul Straus, David J. Owens, Colette Caron, Philip Intlekofer, Andrew Hamilton, Audrey Horwitz, Steven Falchi, Lorenzo Johnson, William Palomba, Lia Noy, Ariela Matasar, Matthew Pongas, Georgios Salles, Gilles Vardhana, Santosha Sanin, Beatriz Wills Yahalom, Joachim Dogan, Ahmet Zelenetz, Andrew Moskowitz, Craig H. |
| author_sort | Moskowitz, Alison J. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9621500 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96215002022-11-01 T099: High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma Moskowitz, Alison J. Shah, Gunjan Schöder, Heiko Ganesan, Nivetha Hancock, Helen Davey, Theresa Perez, Leslie Sohail, Samia Santarosa, Alayna Capadona, Charisse Munayirji, Brittney Kumar, Anita Lahoud, Oscar Batlevi, Connie Hamlin, Paul Straus, David J. Owens, Colette Caron, Philip Intlekofer, Andrew Hamilton, Audrey Horwitz, Steven Falchi, Lorenzo Johnson, William Palomba, Lia Noy, Ariela Matasar, Matthew Pongas, Georgios Salles, Gilles Vardhana, Santosha Sanin, Beatriz Wills Yahalom, Joachim Dogan, Ahmet Zelenetz, Andrew Moskowitz, Craig H. Hemasphere Relapsed/Refractory Lippincott Williams & Wilkins 2022-10-03 /pmc/articles/PMC9621500/ http://dx.doi.org/10.1097/01.HS9.0000890964.54059.2c Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Relapsed/Refractory Moskowitz, Alison J. Shah, Gunjan Schöder, Heiko Ganesan, Nivetha Hancock, Helen Davey, Theresa Perez, Leslie Sohail, Samia Santarosa, Alayna Capadona, Charisse Munayirji, Brittney Kumar, Anita Lahoud, Oscar Batlevi, Connie Hamlin, Paul Straus, David J. Owens, Colette Caron, Philip Intlekofer, Andrew Hamilton, Audrey Horwitz, Steven Falchi, Lorenzo Johnson, William Palomba, Lia Noy, Ariela Matasar, Matthew Pongas, Georgios Salles, Gilles Vardhana, Santosha Sanin, Beatriz Wills Yahalom, Joachim Dogan, Ahmet Zelenetz, Andrew Moskowitz, Craig H. T099: High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma |
| title | T099: High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma |
| title_full | T099: High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma |
| title_fullStr | T099: High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma |
| title_full_unstemmed | T099: High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma |
| title_short | T099: High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma |
| title_sort | t099: high efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase ii study for relapsed and refractory hodgkin lymphoma |
| topic | Relapsed/Refractory |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621500/ http://dx.doi.org/10.1097/01.HS9.0000890964.54059.2c |
| work_keys_str_mv | AT moskowitzalisonj t099highefficacyanddurabilityofsecondlinetherapywithpembrolizumabgemcitabinevinorelbineandliposomaldoxorubicininthephaseiistudyforrelapsedandrefractoryhodgkinlymphoma AT shahgunjan t099highefficacyanddurabilityofsecondlinetherapywithpembrolizumabgemcitabinevinorelbineandliposomaldoxorubicininthephaseiistudyforrelapsedandrefractoryhodgkinlymphoma AT schoderheiko t099highefficacyanddurabilityofsecondlinetherapywithpembrolizumabgemcitabinevinorelbineandliposomaldoxorubicininthephaseiistudyforrelapsedandrefractoryhodgkinlymphoma AT ganesannivetha t099highefficacyanddurabilityofsecondlinetherapywithpembrolizumabgemcitabinevinorelbineandliposomaldoxorubicininthephaseiistudyforrelapsedandrefractoryhodgkinlymphoma AT hancockhelen t099highefficacyanddurabilityofsecondlinetherapywithpembrolizumabgemcitabinevinorelbineandliposomaldoxorubicininthephaseiistudyforrelapsedandrefractoryhodgkinlymphoma AT daveytheresa t099highefficacyanddurabilityofsecondlinetherapywithpembrolizumabgemcitabinevinorelbineandliposomaldoxorubicininthephaseiistudyforrelapsedandrefractoryhodgkinlymphoma AT perezleslie t099highefficacyanddurabilityofsecondlinetherapywithpembrolizumabgemcitabinevinorelbineandliposomaldoxorubicininthephaseiistudyforrelapsedandrefractoryhodgkinlymphoma AT sohailsamia t099highefficacyanddurabilityofsecondlinetherapywithpembrolizumabgemcitabinevinorelbineandliposomaldoxorubicininthephaseiistudyforrelapsedandrefractoryhodgkinlymphoma AT santarosaalayna t099highefficacyanddurabilityofsecondlinetherapywithpembrolizumabgemcitabinevinorelbineandliposomaldoxorubicininthephaseiistudyforrelapsedandrefractoryhodgkinlymphoma AT capadonacharisse t099highefficacyanddurabilityofsecondlinetherapywithpembrolizumabgemcitabinevinorelbineandliposomaldoxorubicininthephaseiistudyforrelapsedandrefractoryhodgkinlymphoma AT munayirjibrittney t099highefficacyanddurabilityofsecondlinetherapywithpembrolizumabgemcitabinevinorelbineandliposomaldoxorubicininthephaseiistudyforrelapsedandrefractoryhodgkinlymphoma AT kumaranita t099highefficacyanddurabilityofsecondlinetherapywithpembrolizumabgemcitabinevinorelbineandliposomaldoxorubicininthephaseiistudyforrelapsedandrefractoryhodgkinlymphoma AT lahoudoscar t099highefficacyanddurabilityofsecondlinetherapywithpembrolizumabgemcitabinevinorelbineandliposomaldoxorubicininthephaseiistudyforrelapsedandrefractoryhodgkinlymphoma AT batleviconnie t099highefficacyanddurabilityofsecondlinetherapywithpembrolizumabgemcitabinevinorelbineandliposomaldoxorubicininthephaseiistudyforrelapsedandrefractoryhodgkinlymphoma AT hamlinpaul t099highefficacyanddurabilityofsecondlinetherapywithpembrolizumabgemcitabinevinorelbineandliposomaldoxorubicininthephaseiistudyforrelapsedandrefractoryhodgkinlymphoma AT strausdavidj t099highefficacyanddurabilityofsecondlinetherapywithpembrolizumabgemcitabinevinorelbineandliposomaldoxorubicininthephaseiistudyforrelapsedandrefractoryhodgkinlymphoma AT owenscolette t099highefficacyanddurabilityofsecondlinetherapywithpembrolizumabgemcitabinevinorelbineandliposomaldoxorubicininthephaseiistudyforrelapsedandrefractoryhodgkinlymphoma AT caronphilip t099highefficacyanddurabilityofsecondlinetherapywithpembrolizumabgemcitabinevinorelbineandliposomaldoxorubicininthephaseiistudyforrelapsedandrefractoryhodgkinlymphoma AT intlekoferandrew t099highefficacyanddurabilityofsecondlinetherapywithpembrolizumabgemcitabinevinorelbineandliposomaldoxorubicininthephaseiistudyforrelapsedandrefractoryhodgkinlymphoma AT hamiltonaudrey t099highefficacyanddurabilityofsecondlinetherapywithpembrolizumabgemcitabinevinorelbineandliposomaldoxorubicininthephaseiistudyforrelapsedandrefractoryhodgkinlymphoma AT horwitzsteven t099highefficacyanddurabilityofsecondlinetherapywithpembrolizumabgemcitabinevinorelbineandliposomaldoxorubicininthephaseiistudyforrelapsedandrefractoryhodgkinlymphoma AT falchilorenzo t099highefficacyanddurabilityofsecondlinetherapywithpembrolizumabgemcitabinevinorelbineandliposomaldoxorubicininthephaseiistudyforrelapsedandrefractoryhodgkinlymphoma AT johnsonwilliam t099highefficacyanddurabilityofsecondlinetherapywithpembrolizumabgemcitabinevinorelbineandliposomaldoxorubicininthephaseiistudyforrelapsedandrefractoryhodgkinlymphoma AT palombalia t099highefficacyanddurabilityofsecondlinetherapywithpembrolizumabgemcitabinevinorelbineandliposomaldoxorubicininthephaseiistudyforrelapsedandrefractoryhodgkinlymphoma AT noyariela t099highefficacyanddurabilityofsecondlinetherapywithpembrolizumabgemcitabinevinorelbineandliposomaldoxorubicininthephaseiistudyforrelapsedandrefractoryhodgkinlymphoma AT matasarmatthew t099highefficacyanddurabilityofsecondlinetherapywithpembrolizumabgemcitabinevinorelbineandliposomaldoxorubicininthephaseiistudyforrelapsedandrefractoryhodgkinlymphoma AT pongasgeorgios t099highefficacyanddurabilityofsecondlinetherapywithpembrolizumabgemcitabinevinorelbineandliposomaldoxorubicininthephaseiistudyforrelapsedandrefractoryhodgkinlymphoma AT sallesgilles t099highefficacyanddurabilityofsecondlinetherapywithpembrolizumabgemcitabinevinorelbineandliposomaldoxorubicininthephaseiistudyforrelapsedandrefractoryhodgkinlymphoma AT vardhanasantosha t099highefficacyanddurabilityofsecondlinetherapywithpembrolizumabgemcitabinevinorelbineandliposomaldoxorubicininthephaseiistudyforrelapsedandrefractoryhodgkinlymphoma AT saninbeatrizwills t099highefficacyanddurabilityofsecondlinetherapywithpembrolizumabgemcitabinevinorelbineandliposomaldoxorubicininthephaseiistudyforrelapsedandrefractoryhodgkinlymphoma AT yahalomjoachim t099highefficacyanddurabilityofsecondlinetherapywithpembrolizumabgemcitabinevinorelbineandliposomaldoxorubicininthephaseiistudyforrelapsedandrefractoryhodgkinlymphoma AT doganahmet t099highefficacyanddurabilityofsecondlinetherapywithpembrolizumabgemcitabinevinorelbineandliposomaldoxorubicininthephaseiistudyforrelapsedandrefractoryhodgkinlymphoma AT zelenetzandrew t099highefficacyanddurabilityofsecondlinetherapywithpembrolizumabgemcitabinevinorelbineandliposomaldoxorubicininthephaseiistudyforrelapsedandrefractoryhodgkinlymphoma AT moskowitzcraigh t099highefficacyanddurabilityofsecondlinetherapywithpembrolizumabgemcitabinevinorelbineandliposomaldoxorubicininthephaseiistudyforrelapsedandrefractoryhodgkinlymphoma |